GlobeNewswire

NRT Acquires NCC, Leading Provider of Next Generation Credit Marker and AML Information Services to Global Gaming Operators

Dela

NCC is a strong addition to the NRT family of businesses, enabling the company to fortify a leading position in casino credit platforms and further enhancing NRT's value proposition by providing casino operators opportunities to grow revenue, reduce risk, meet compliance regulations, and better serve their VIP guests.

LAS VEGAS, April  11, 2018  (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT"), a global technology leader of current and next generation payment systems, specialized financial/marketing self-serve kiosks, and digital and mobile experiences, announced that it has acquired the assets of privately held National Cred-A-Chek, Inc. ("NCC")  the leading provider of information services for underwriting credit markers to more than 300 casino operators around the world. Terms of the agreement were not disclosed.

The NCC acquisition follows closely on the heels of NRT's recently announced eMarker® acquisition, a solution which uses mobile technology and digital signatures to eliminate the cumbersome process of managing paper-issued casino markers, thereby expediting the marker process for casinos and their patrons.

NCC is a versatile and essential source of data on which casinos rely to make informed decisions regarding the underwriting of credit markers for their guests. By leveraging this powerful FCRA-compliant (Fair Credit Reporting Act) cloud-based platform in conjunction with eMarker®, NRT will become the first and only end-to-end solution for credit application hosting, bank verification data, gaming credit history data, third-party credit bureau data, ID validation, AML compliance, issuance, processing, storage, redemption, and repayment of casino markers.

"NCC is a great company with a long and successful history of using data and technology to deliver unparalleled insight into casino guests and their credit worthiness," said Christine Landis, President of NCC. "Our service goes back 40 years, and it has been a privilege to carry on Diane Hunt's legacy. Now is the right time to pass it off to a forward-thinking management team that can leverage our global operating model and technology platform."

"This acquisition opens an exciting opportunity and is a strong fit for NRT.  It reinforces our strategic focus to be a leading global casino information and data analytics solutions provider," said John Dominelli, NRT's Founder and President. "We're delighted to count on the expertise of NCC's management and staff, and we welcome them into the NRT family."

NRT's recent investment in Gaming Analytics.AI will further set the stage for the next evolution of technology enhancements for the gaming industry, allowing NRT to incorporate AI search-driven analytics with insights and contexts of marker player behavior and preferences.

"NCC and eMarker together create a groundbreaking end-to-end marker underwriting and issuance solution for casinos," said Kirk Sanford, Sightline Payments Founder and CEO. "Through NCC, we will have a robust platform connected to hundreds of casinos from which to offer advanced data analytics services for underwriting processes and 'next generation' risk scoring information."

Mrs. Landis added, "Our immediate objective is consistency and continuity for our customers and the NCC team members. I will stay on through a transition period to bring all the benefits of the combined companies together as quickly as possible while ensuring that NCC's solutions remain as nimble and well-organized as ever, and to efficiently incorporate more capabilities to accelerate performance for our valued customers."

About NCC

For the past 40 years, NCC's mission has been to help our over 300 casino partners around the world to optimize risk-based decisions for underwriting of casino credit and to meet AML compliance requirements. Our FCRA-compliant cloud-based platform automates marker credit applications and consolidates multidimensional reports of casino marker, front money, and check cashing information, bank verification data, as well as third-party credit bureau, identity validation, and KYC tools.

About NRT & Sightline

On closing of the pending merger, NRT Sightline will be the global leader in the design and development of enterprise platforms for the gaming industry, including current and next generation payment systems, specialized self-serve financial/marketing kiosks, big data analytics utilizing artificial intelligence and gamification, credit marker information services, and digital and mobile experiences. Through our global family of companies, we enable more than 1 billion physical and digital commerce experiences at over 750 casino properties worldwide, including the top 25 largest casino corporations.  By seamlessly combining technological innovation with strategic partnerships, our companies create the most convenient, reliable, and secure omni-channel payment ecosystem for casino operators and their guests. NRT and Sightline have been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for our Play+(TM) cloud-based cashless funding platform. Our collective solutions are used by casinos, lotteries, race and sports, banking & retailers around the world.

For further information about this acquisition, please contact:  Michael Dominelli, NRT's SVP Marketing mdominelli@nrttech.com

For more information about Sightline or its pending merger with NRT, please contact:  Omer Sattar, Sightline's EVP Strategic Relationships osattar@sightlinepayments.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum